Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20323503 | 0.81 | DRD1 (0.42) | CA2CA1PSIP1SMN1; SMN2CA12 | |
| SCHEMBL2817521 | 0.77 | GAA (0.53) | CA2CA1SMN1; SMN2CA12CA4 | |
| SCHEMBL20300410 | 0.76 | CA2 (0.44) | CA2CA1SMN1; SMN2CA12CA4 | |
| SCHEMBL11144542 | 0.76 | PSIP1 (0.52) | CA2CA1PSIP1SMN1; SMN2CA12 | |
| SCHEMBL398570 | 0.76 | ENPP2 (0.50) | CA2CA1PTGS2 | |
| SCHEMBL710799 | 0.74 | PSIP1 (0.63) | CA2CA1PSIP1SMN1; SMN2 | |
| SCHEMBL25267650 | 0.73 | CA12 (0.50) | CA2CA1SMN1; SMN2CA12CA4 | |
| SCHEMBL20323486 | 0.73 | F2 (0.41) | SMN1; SMN2PTGS2 | |
| SCHEMBL20300446 | 0.72 | CA2 (0.42) | CA2CA1PSIP1SMN1; SMN2CA12 | |
| SCHEMBL20323436 | 0.71 | CA2 (0.41) | CA2CA1PSIP1SMN1; SMN2UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2024-09-19 | — | — | US | disclosed |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2024-07-09 | — | — | US | disclosed |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2024-07-09 | — | — | US | disclosed |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2024-07-09 | — | — | US | disclosed |
| US-20210347765-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORPORATION | 2021-11-11 | — | — | US | disclosed |
| US-20210347765-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORPORATION | 2021-11-11 | — | — | US | disclosed |
| EP-3558981-B1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| EP-3558981-B1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-20200299280-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| US-20200299280-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| US-10717726-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2020-07-21 | — | — | US | disclosed |
| US-10717726-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2020-07-21 | — | — | US | disclosed |
| EP-3558981-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | Orion Corporation (FI) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018115591-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORPORATION (FI) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018115591-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORPORATION (FI) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717726-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | CA2 2703/4885CA1 2622/4885PSIP1 2752/4885 |
| US-20210347765-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | CA2 2703/4885CA1 2622/4885PSIP1 2752/4885 |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | CA2 2703/4885CA1 2622/4885PSIP1 2752/4885 |
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | CA2 2874/4885CA1 2748/4885PSIP1 2420/4885 |
| US-20200299280-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | CA2 2703/4885CA1 2622/4885PSIP1 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.